Tags: Cancer | lung cancer | Tafinlar | dabrafenib | FDA breakthrough designation

'Breakthrough' Cancer Drug Fast-Tracked for Approval

Monday, 13 Jan 2014 12:38 PM


 
British pharmaceutical company GlaxoSmithKline said its Tafinlar cancer treatment had been given FDA breakthrough therapy designation for lung cancer, meaning the drug will be fast-tracked within the U.S. regulatory system.
 
GSK said that Tafinlar, also known as dabrafenib, was designated an FDA breakthrough therapy on Monday following interim results from an ongoing Phase II study.
Tafinlar is already approved for melanoma, the deadliest form of skin cancer.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
Health-News
British pharmaceutical company GlaxoSmithKline said its Tafinlar cancer treatment had been given FDA breakthrough therapy designation for lung cancer, meaning the drug will be fast-tracked within the U.S. regulatory system. GSK said that Tafinlar, also known as dabrafenib,...
lung cancer,Tafinlar,dabrafenib,FDA breakthrough designation
67
2014-38-13
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved